Literature DB >> 33157015

Zmat3 Is a Key Splicing Regulator in the p53 Tumor Suppression Program.

Kathryn T Bieging-Rolett1, Alyssa M Kaiser1, David W Morgens2, Anthony M Boutelle1, Jose A Seoane3, Eric L Van Nostrand4, Changyu Zhu5, Shauna L Houlihan5, Stephano S Mello1, Brian A Yee4, Jacob McClendon1, Sarah E Pierce2, Ian P Winters2, Mengxiong Wang1, Andrew J Connolly6, Scott W Lowe5, Christina Curtis3, Gene W Yeo4, Monte M Winslow7, Michael C Bassik7, Laura D Attardi8.   

Abstract

Although TP53 is the most commonly mutated gene in human cancers, the p53-dependent transcriptional programs mediating tumor suppression remain incompletely understood. Here, to uncover critical components downstream of p53 in tumor suppression, we perform unbiased RNAi and CRISPR-Cas9-based genetic screens in vivo. These screens converge upon the p53-inducible gene Zmat3, encoding an RNA-binding protein, and we demonstrate that ZMAT3 is an important tumor suppressor downstream of p53 in mouse KrasG12D-driven lung and liver cancers and human carcinomas. Integrative analysis of the ZMAT3 RNA-binding landscape and transcriptomic profiling reveals that ZMAT3 directly modulates exon inclusion in transcripts encoding proteins of diverse functions, including the p53 inhibitors MDM4 and MDM2, splicing regulators, and components of varied cellular processes. Interestingly, these exons are enriched in NMD signals, and, accordingly, ZMAT3 broadly affects target transcript stability. Collectively, these studies reveal ZMAT3 as a novel RNA-splicing and homeostasis regulator and a key component of p53-mediated tumor suppression.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CRISPR screen; Mdm4; RBP; RNAi screen; Zmat3; alternative splicing; hepatocellular carcinoma; lung adenocarcinoma; p53; tumor suppression

Mesh:

Substances:

Year:  2020        PMID: 33157015      PMCID: PMC7654708          DOI: 10.1016/j.molcel.2020.10.022

Source DB:  PubMed          Journal:  Mol Cell        ISSN: 1097-2765            Impact factor:   17.970


  94 in total

1.  Somatic activation of the K-ras oncogene causes early onset lung cancer in mice.

Authors:  L Johnson; K Mercer; D Greenbaum; R T Bronson; D Crowley; D A Tuveson; T Jacks
Journal:  Nature       Date:  2001-04-26       Impact factor: 49.962

2.  p53 efficiently suppresses tumor development in the complete absence of its cell-cycle inhibitory and proapoptotic effectors p21, Puma, and Noxa.

Authors:  Liz J Valente; Daniel H D Gray; Ewa M Michalak; Josefina Pinon-Hofbauer; Alex Egle; Clare L Scott; Ana Janic; Andreas Strasser
Journal:  Cell Rep       Date:  2013-05-09       Impact factor: 9.423

3.  p53 Represses the Mevalonate Pathway to Mediate Tumor Suppression.

Authors:  Sung-Hwan Moon; Chun-Hao Huang; Shauna L Houlihan; Kausik Regunath; William A Freed-Pastor; John P Morris; Darjus F Tschaharganeh; Edward R Kastenhuber; Anthony M Barsotti; Rachel Culp-Hill; Wen Xue; Yu-Jui Ho; Timour Baslan; Xiang Li; Allison Mayle; Elisa de Stanchina; Lars Zender; David R Tong; Angelo D'Alessandro; Scott W Lowe; Carol Prives
Journal:  Cell       Date:  2018-12-20       Impact factor: 41.582

4.  Glutathione synthetase. Purification from rat kidney and mapping of the substrate binding sites.

Authors:  L Oppenheimer; V P Wellner; O W Griffith; A Meister
Journal:  J Biol Chem       Date:  1979-06-25       Impact factor: 5.157

5.  Therapeutic Targeting of RNA Splicing Catalysis through Inhibition of Protein Arginine Methylation.

Authors:  Jia Yi Fong; Luca Pignata; Pierre-Alexis Goy; Kimihito Cojin Kawabata; Stanley Chun-Wei Lee; Cheryl M Koh; Daniele Musiani; Enrico Massignani; Andriana G Kotini; Alex Penson; Cheng Mun Wun; Yudao Shen; Megan Schwarz; Diana Hp Low; Alexander Rialdi; Michelle Ki; Heike Wollmann; Slim Mzoughi; Florence Gay; Christine Thompson; Timothy Hart; Olena Barbash; Genna M Luciani; Magdalena M Szewczyk; Bas J Wouters; Ruud Delwel; Eirini P Papapetrou; Dalia Barsyte-Lovejoy; Cheryl H Arrowsmith; Mark D Minden; Jian Jin; Ari Melnick; Tiziana Bonaldi; Omar Abdel-Wahab; Ernesto Guccione
Journal:  Cancer Cell       Date:  2019-08-12       Impact factor: 31.743

6.  Transcriptomic Characterization of SF3B1 Mutation Reveals Its Pleiotropic Effects in Chronic Lymphocytic Leukemia.

Authors:  Lili Wang; Angela N Brooks; Jean Fan; Youzhong Wan; Rutendo Gambe; Shuqiang Li; Sarah Hergert; Shanye Yin; Samuel S Freeman; Joshua Z Levin; Lin Fan; Michael Seiler; Silvia Buonamici; Peter G Smith; Kevin F Chau; Carrie L Cibulskis; Wandi Zhang; Laura Z Rassenti; Emanuela M Ghia; Thomas J Kipps; Stacey Fernandes; Donald B Bloch; Dylan Kotliar; Dan A Landau; Sachet A Shukla; Jon C Aster; Robin Reed; David S DeLuca; Jennifer R Brown; Donna Neuberg; Gad Getz; Kenneth J Livak; Matthew M Meyerson; Peter V Kharchenko; Catherine J Wu
Journal:  Cancer Cell       Date:  2016-11-03       Impact factor: 31.743

7.  Next-generation libraries for robust RNA interference-based genome-wide screens.

Authors:  Martin Kampmann; Max A Horlbeck; Yuwen Chen; Jordan C Tsai; Michael C Bassik; Luke A Gilbert; Jacqueline E Villalta; S Chul Kwon; Hyeshik Chang; V Narry Kim; Jonathan S Weissman
Journal:  Proc Natl Acad Sci U S A       Date:  2015-06-15       Impact factor: 11.205

8.  A genomewide study identifies the Wnt signaling pathway as a major target of p53 in murine embryonic stem cells.

Authors:  Kyoung-Hwa Lee; Mangmang Li; Aleksandra M Michalowski; Xinyue Zhang; Hongling Liao; Lingyi Chen; Yang Xu; Xiaolin Wu; Jing Huang
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-14       Impact factor: 11.205

9.  p53-dependent Nestin regulation links tumor suppression to cellular plasticity in liver cancer.

Authors:  Darjus F Tschaharganeh; Wen Xue; Diego F Calvisi; Matthias Evert; Tatyana V Michurina; Lukas E Dow; Ana Banito; Sarah F Katz; Edward R Kastenhuber; Susann Weissmueller; Chun-Hao Huang; Andre Lechel; Jesper B Andersen; David Capper; Lars Zender; Thomas Longerich; Grigori Enikolopov; Scott W Lowe
Journal:  Cell       Date:  2014-07-31       Impact factor: 41.582

10.  Stage-specific sensitivity to p53 restoration during lung cancer progression.

Authors:  David M Feldser; Kamena K Kostova; Monte M Winslow; Sarah E Taylor; Chris Cashman; Charles A Whittaker; Francisco J Sanchez-Rivera; Rebecca Resnick; Roderick Bronson; Michael T Hemann; Tyler Jacks
Journal:  Nature       Date:  2010-11-25       Impact factor: 49.962

View more
  16 in total

Review 1.  MDM4 alternative splicing and implication in MDM4 targeted cancer therapies.

Authors:  Jin Wu; Guanting Lu; Xinjiang Wang
Journal:  Am J Cancer Res       Date:  2021-12-15       Impact factor: 6.166

Review 2.  Delivery of CRISPR-Cas9 system for screening and editing RNA binding proteins in cancer.

Authors:  Jingyue Yan; Diana D Kang; Gillian Turnbull; Yizhou Dong
Journal:  Adv Drug Deliv Rev       Date:  2021-11-09       Impact factor: 15.470

Review 3.  Of the many cellular responses activated by TP53, which ones are critical for tumour suppression?

Authors:  Gemma L Kelly; Andreas Strasser; Annabella F Thomas
Journal:  Cell Death Differ       Date:  2022-04-08       Impact factor: 12.067

4.  Zmat3 splices together p53-dependent tumor suppression.

Authors:  Kathryn T Bieging-Rolett; Laura D Attardi
Journal:  Mol Cell Oncol       Date:  2021-04-29

Review 5.  p53 and Tumor Suppression: It Takes a Network.

Authors:  Anthony M Boutelle; Laura D Attardi
Journal:  Trends Cell Biol       Date:  2021-01-28       Impact factor: 20.808

6.  Synergistic action of WDR5 and HDM2 inhibitors in SMARCB1-deficient cancer cells.

Authors:  Andrea C Florian; Chase M Woodley; Jing Wang; Brian C Grieb; Macey J Slota; Kiana Guerrazzi; Chih-Yuan Hsu; Brittany K Matlock; David K Flaherty; Shelly L Lorey; Stephen W Fesik; Gregory C Howard; Qi Liu; April M Weissmiller; William P Tansey
Journal:  NAR Cancer       Date:  2022-03-03

7.  ZMAT3 hypomethylation contributes to early senescence of preadipocytes from healthy first-degree relatives of type 2 diabetics.

Authors:  Rosa Spinelli; Pasqualina Florese; Luca Parrillo; Federica Zatterale; Michele Longo; Vittoria D'Esposito; Antonella Desiderio; Annika Nerstedt; Birgit Gustafson; Pietro Formisano; Claudia Miele; Gregory Alexander Raciti; Raffaele Napoli; Ulf Smith; Francesco Beguinot
Journal:  Aging Cell       Date:  2022-02-11       Impact factor: 11.005

Review 8.  Shifting the paradigms for tumor suppression: lessons from the p53 field.

Authors:  Thibaut Barnoud; Alexandra Indeglia; Maureen E Murphy
Journal:  Oncogene       Date:  2021-06-08       Impact factor: 9.867

9.  NUAK2 and RCan2 participate in the p53 mutant pro-tumorigenic network.

Authors:  Eleonora Mammarella; Carlotta Zampieri; Emanuele Panatta; Gerry Melino; Ivano Amelio
Journal:  Biol Direct       Date:  2021-08-04       Impact factor: 4.540

10.  Understanding p53 tumour suppressor network.

Authors:  Emanuele Panatta; Carlotta Zampieri; Gerry Melino; Ivano Amelio
Journal:  Biol Direct       Date:  2021-08-06       Impact factor: 4.540

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.